Introduction
Immunoglobulins bind antigens through the variable (V) regions of the two-polypeptide components, the light (L) and the heavy (H) chains. Sequence variability of immunoglobulin V regions is generated by differential V region genes usage, genetic recombination and somatic hypermutation. The particular combination of the two V regions define the idiotype (Id), a unique antigenic structural feature that can be specifically detected by anti-Id antibodies. Since idiotypes reflect the uniqueness of each immunoglobulin molecule, and each B lymphocyte expresses a single arrangement of light and heavy chain V regions, idiotypes represent clonal signatures of individual B cells. In the case of surface Ig + B cell malignancies, such as B cell lymphomas, idiotypes are therefore ideal tumour-associated antigens that can be used as targets for immunotherapy. Active immunisation using idiotypic protein [1] [2] [3] and more recently, genetic immunisation with plasmid DNA encoding tumour-derived Ig variable regions [4] [5] [6] [7] was found to be effective in inducing anti-Id antibodies and protection against tumour challenge. Our laboratory has demonstrated that, in the murine BCL1 lymphoma model, genetic vaccination with a construct containing the Id BCL1 in a scFv format, fused to the CH3 exon of the human IgG1 constant region was able to induce high titres of anti-Id antibodies and resistance to tumour challenge. 7 We showed that both tumourderived V regions were essential for the induction of protective immunity.
Recent studies indicated the importance of direct regulatory effects of anti-Id antibodies on tumour growth. 8, 9 This raises the question of the binding specificity of antiidiotypic antibodies. Although several strategies to induce high titres of anti-lymphoma idiotype antibodies using scFv DNA vaccines have been described, little is known on the structural basis of the idiotype/antiidiotype interaction following DNA vaccination. The contribution of V H and V L variable domains to the idiotype structure has been investigated in other systems. Most of the studies involved the use of mAbs, yielding different results. There are reports in which the reactivity of mAbs was shown to depend on the presence of both parental V regions, [10] [11] [12] as well as cases in which the binding was mapped on the V H , regardless of the associated V L . [13] [14] [15] Analysis of the polyclonal anti-Id responses of sera raised against the major Id (CRIA) of anti-p-azobenzenearsonate revealed that 20 to 35% of anti-Id antibodies reacted with high affinity with H chains recombined with non-CRIA related L chains. 16 So far, no data have been reported regarding the speci-ficity of anti-Id responses following DNA immunisation. In this study, we explored the contribution of the two tumour-derived V regions in the induction of the anti-Id immune response by scFv DNA vaccination, as well as the specificity of the polyclonal anti-Id antibodies for combined V L /V H versus not combined V L or V H determinants. We show that genetic immunisation with plasmids encoding scFv idiotypes induced a polyclonal immune response that is exclusively directed against determinants depending on the immunising V L /V H association. On the contrary, sera raised by immunisation with purified scFv protein reacted with V L BCL1 and V H BCL1 determinants associated with irrelevant V region partners.
Results

Induction of anti-Id antibodies by scFv DNA immunisation
We have previously demonstrated that genetic immunisation with a scFv idiotype construct was able to induce a protective response against the BCL1 lymphoma. 7 The gene construct contained the two BCL1 variable regions in the V L -V H orientation, separated by an 18-amino acid linker that ensures optimal folding of the scFv molecules.
In agreement with studies in other lymphoma models, 4 the fusion of a xenogeneic domain (the CH3 domain of the human IgG1 constant region) to the idiotype-encoding sequence, proved to be essential for the induction of anti-Id antibodies (data not shown), indicating the need to break T cell tolerance. In addition, this scFvhuCH3 design (called SIP) 17 leads to efficient expression and secretion of the encoded protein.
In order to evaluate the relative contribution of tumour-derived V L and V H in the induction of the anti-Id antibody response, we generated two different constructs (pV L BCL1 /V H 6C6 and pV L
6C6
/V H BCL1 ) containing a scFv with either V L or V H of BCL1 paired, respectively, to V H or V L of an irrelevant murine monoclonal antibody, mAb 6C6. 18 The 6C6 antibody was chosen because its V regions have low homology to those of BCL1. While mAb 6C6 has a light chain and a V H corresponding to family VI, BCL1 light chain is (family I) and the V H corresponds to family XXIV. As a control, we also constructed a complete scFv 6C6 -huCH3 (p6C6) (Figure 1a ). All these constructs showed similar levels of expression in transfected Sp2/0 cells.
The ability of each construct to induce an antibody response against the BCL1 idiotype (Id BCL1 ) and against the human ␥1-CH3 portion was analysed by ELISA on sera of animals receiving three shots of DNA-coated gold particles. While serum levels of antibodies directed against the hu-CH3 domain were comparable for all four constructs, both chimeric pV
as well as the control p6C6 failed to evoke detectable levels of anti-Id BCL1 antibodies ( Figure 1b) . Immune sera were also tested by flow cytometry for their ability to bind the Id expressed on the surface of BCL1 lymphoma cells ( Figure 1c) . Independently from the dilution tested, only sera from animals immunised with pBCL1 were able to stain BCL1 cells, thus confirming the inability of either of the two tumour-derived V regions associated with an irrelevant partner to elicit antibodies against the parental idiotype. Hereby, the pairing of both parental V L and V H in a scFv was essential to induce antibodies against the Id BCL1 .
Specificity of anti-Id antibodies for V L and V H combined determinants
We investigated the overall polyclonal anti-Id antibody response raised by pBCL1, in terms of reactivity against specific V L , V H , or combined V L /V H determinants expressed in the context of folded idiotypes. To address this issue we developed a genetic strategy to display idiotypes arising from different V region pairings on the surface of transfected cells. We designed a membrane version of SIP (⑀-mSIP), based on the human membrane IgE isotype. These molecules contain a scFv fused to the C-terminal region of the human membrane IgE H chain, from ⑀CH4 down to the cytoplamic tail. 19 ⑀-mSIP are efficiently expressed as membrane proteins 20 allowing flow cytometry visualisation of anti-Id Abs reacting with the displayed idiotypic determinants. DNA cassettes encoding scFvs of BCL1, 6C6 and the two BCL1/6C6 chimera were cloned into the ⑀-mSIP vector ( Figure 1a ) and transfected into the Ig − , non-secreting mouse myeloma cell line Sp2/0. Positive clones showing comparable expression levels for each construct were selected ( Figure 2b ).
Proper display of the Id BCL1 on Sp2/0 cells transfected with ⑀-mBCL1 was demonstrated by flow cytometry using two specific reagents: an anti-Id BCL1 mAb (10/4A12) 21 and the anti-Id serum raised by pBCL1 ( Figure 2c ). In addition, since mAb 10/4A12 binds to V H of BCL1 21 we tested it on the V L
6C6
/V H BCL1 chimera. As shown in Figure 2c , mAb 10/4A12 stained SP2/0 transfected cells, indicating that V H BCL1 is also properly displayed in the context of a non-parental Id. No cross-reactivity was observed with sera induced by p6C6 on cells displaying the BCL1 idiotype, thus excluding the presence of antibodies directed against the 18 aa linker between V L and V H , identical for all the soluble and membrane scFvs (see below).
We next examined the reactivity of sera induced by the protective pBCL1 construct To extend the analysis to other cases, we performed crossed binding analysis of the displayed idiotypes with sera raised by pV L BCL1 /V H 6C6 , pV L 6C6 /V H BCL1 and p6C6. Flow cytometry data shown in Figure 4 clearly demonstrated that each membrane-displayed idiotype was only recognised by antibodies induced by the corresponding soluble scFv. Noteworthy, no detectable cross-reactivity was observed by any of the immune sera raised with scFvs containing only one of the two V regions. All four cases presented provided strong evidence that the antiId immune response induced by our scFv-huCH3 genetic vaccination was strictly confined to conformational V L /V H combined determinants with no reactivity against determinants displayed on either V L or V H , independently from the other V region partner. The inability of sera raised with pBCL1 to recognise purified BCL1 IgM protein in Western blotting confirmed that DNA vaccination induced exclusively conformational anti-Id Ab (data not shown; see also Figure 5 ). 
Reactivity against chain-specific determinants
The lack of reactivity against chain-specific determinants suggested that the response against epitopes deriving from the V L /V H association was highly dominant. This implies presentation to the immune system of a conformational idiotype, as the one expressed on the native immunoglobulin. This is the case of our immunising soluble scFv molecules, which are efficiently secreted in tissue culture supernatants of transfected cells maintaining the antigen-binding capacity. 17 It was then interesting to examine whether the observed reactivity was peculiar to genetic vaccination. To analyse with the same system the reactivity of sera induced by the classical protocol of protein immunisation, we immunised mice with the scFv BCL1 -huCH3 protein purified from SP2/0 cells transfected with pBCL1 ( Figure 1a) . We chose for the analysis protein-induced sera yielding ELISA titres of anti hu-CH3 antibodies identical to that induced by pBCL1 DNA. Interestingly, flow cytometry (Figure 5a (Figure 5b ). These results demonstrate that the specificity of the anti-Id antibody response depends on the way in which the same protein antigen is presented to the immune system.
Gene Therapy
Discussion
Active immunotherapy of B cell malignancies using idiotypic protein and DNA vaccination has been successful in murine lymphoma models. Although several reports indicated that anti-Id antibodies play an essential role in the rejection of tumour cells. 6, 8, 9, 22, 23 the binding of anti-Id antibodies to the idiotype on the surface of lymphoma cells has not been mapped. In the present study we explored the structural basis of the Id/anti-Id interaction upon immunisation with scFv plasmid DNA. Starting from our BCL1 model system we generated four different Id genetic constructs, two parental (BCL1 and 6C6) and two chimeric (mismatched BCL1/6C6 V region associations) that were used both as immunogens in a soluble SIP version (scFv-huCH3), as well as displayed target idiotypes in their membrane-bound forms (⑀-mSIP).
Our strategy is particularly relevant for the analysis of the Id/anti-Id interaction in native-like conditions. In flow cytometry, as opposed to ELISA tests, Ids are displayed on the surface of living cells rather than purified and coated on a plastic support. In addition, each V region can be analysed independently from its own partner, but folded as it would be in the original idiotype. Moreover, the idiotype protein displayed in the scFv format is identical to the one used to elicit the immune response.
We demonstrated that the parental V regions association in our DNA vaccine is an absolute requirement to induce anti-Id antibodies against the BCL1 IgM. The antiId BCL1 antibodies induced by our scFv DNA vaccination were previously shown to induce protection against tumour challenge. 7 In this report, we show that these antibodies are directed exclusively against conformational combined V L /V H determinants. Although it is likely that most anti-Id antibodies recognise epitopes formed by combined V L /V H sequences, it cannot be excluded that some recognise determinants on a single V region, whose conformations are strictly dependent on the other V region partner. We extended the analysis to three additional idiotypes: one containing V regions from an unrelated murine mAb (6C6) and two chimeric Id generated by mismatching BCL1 and 6C6 V regions. Crossed analysis of the four different immune sera on the four membrane displayed idiotypes showed that, in all cases, the anti-Id immune response was directed exclusively at the original immunising V L /V H combination, with complete absence of antibodies recognising determinants in any of the single V regions displayed in the context of a different idiotype.
These data indicated that epitopes formed by the V L /V H association are highly dominant, inducing an immune response in which antibodies against them become the major component. However, epitopes displayed on single V regions exist and are immunogenic, as demonstrated by the reactivity of scFv BCL1 -huCH3 protein-induced sera. As expected, the protein induced response was also protective upon BCL1 tumour cell challenge (data not shown). The phenomenon of dominance might be due to the higher avidity or higher representation of lymphocytes reacting with antigenic structures peculiar to V L /V H associations, thus resulting in sequestration of the available antigen by these specific lymphocytes. In the case of protein immunisation, that involves presentation to the immune system of larger amounts of antigen than DNA immunisation, the higher availability of antigen would suffice to stimulate a broader range of idiotype-specific lymphocytes, including those (presumably less reactive) against chain-specific epitopes. On the contrary, genetic immunisation relies on small amounts of antigen produced and assembled by cells of the host. In mammalian cells, a protein directed to the secretory pathway encounters the endoplasmic reticulum quality control machinery that promotes the release of correctly folded proteins. 24 
Gene Therapy
For this reason, it is likely that following genetic vaccination, a high percentage of properly folded molecules are secreted and rendered available for processing by the immune system. In protein immunisation, ex-vivo treatments such as purification and mixing with adjuvant, may affect folding of a fraction of the protein disclosing otherwise hidden epitopes. However, we did not observe any differences in the specificity of the anti-Id BCL1 response induced by protein immunisations with or without Freund's adjuvant. In both cases the sera reacted with the Id BCL1 , as well as with the two chimeric Ids (data not shown).
The data presented indicate that our scFv DNA vaccination design results in a highly specific anti-idiotypic immune response that strictly depends on the quaternary structure of the antigen. Although we analysed this phenomenon only in the case of V L /V H domains, the indication that DNA vaccination induces conformational antibodies can also be of interest for other antigens.
It has been suggested that binding of anti-Id antibodies to the idiotype on lymphoma cells can result in direct killing of tumour cells without recruitment of other effector mechanism. 8, 9 The degree of growth inhibition mediated by different antibodies directed against the lymphoma immunoglobulin was shown to depend on the extent of crosslinking. 25 This may in turn depend on the orientation of the target epitopes, 26 as well as on the affinity of the crosslinker. 27 In this setting, it is worth mentioning that DNA vaccination was shown to be as efficient as protein immunisation in inducing protection, although total levels of anti-Id antibodies against the lymphoma immunoglobulin were much lower. 
Materials and methods
Mice, cell lines and transfections
Ten to 12-week-old Balb/c mice were obtained from Harlan (Milan, Italy) and housed at the ICGEB animal house. BCL1 is a spontaneous B cell leukemia/lymphoma of BALB/c origin that expresses high levels of surface IgM/. 28 The hybridoma 123bcl1 secreting BCL1 IgM was kindly provided by Dr FK Stevenson (Tenovus Laboratory, Southampton University Hospital Trust, Southampton, UK). The Ig − non-secreting mouse myeloma Sp2/0 cell line used for transfection experiments was purchased from the American Type Culture Collection (Rockville, MD, USA). Transfections were performed by electroporation as described elsewhere, 29 using 400 g/ml of G418 (Geneticin; Life Technologies, Inc., Gaithersburg, MD, USA) for selection of Sp2/0 clones.
Idiotypic constructs
Cloning of pBCL1 and p6C6 (EMBL accession number X985337 and X98538) has been described in detail previously. 7, 15 
/V H BCL1 and p6C6 into the ⑀-mSIP vector 20 that contains the C-terminal region of the short isoform of human membrane IgE ⑀H chain (⑀CH4, EMPD, transmembrane and cytoplamic domains).
Immunisations
For DNA vaccination, mice were immunised three times intradermally using the BioRad gene delivery device (BioRad, Hercules, CA, USA). The abdominal area of mice was shaved, and 1 m gold particles carrying 1-3 g DNA were shot at 400 psi, every 2 weeks For protein immunisation, the BCL1 scFv protein was affinity-purified from tissue culture supernantants of Sp2/0 cells transfected with pBCL1 using a CNBr-activated Sepharose 4B resin (Pharmacia Biotech, Uppsala, Sweden) conjugated to goat anti-human IgG Ab (Dako, Glostrup, Denmark). The purified protein in PBS was injected subcutaneously three times at 2-week intervals, using 25 g of protein per mouse in a total volume of 100 l. For immunisations with adjuvant, 25 g/mouse of protein in CFA were injected subcutaneously three times at 2-week intervals. Sera were collected via retroorbital puncture 2 weeks after the last boost.
ELISA and FACS analysis
Anti-idiotypic antibody levels in immune sera were measured by ELISA on plates coated with 3 g/ml of BCL1 IgM protein immunopurified from the 123bcl1 hybridoma supernatant. Reactivity against the human CH3 portion was determined using plates coated with 3 g/ml of human IgG (Sigma). Immune sera were serially diluted and bound Abs were detected with (HRPO)-conjugated goat anti mouse IgG (Kirkegaard and Perry, Gaithersburg, MD, USA). To detect the expression of the ⑀-m SIPs, Sp2/0 trasfected cells were stained with FITC conjugated goat anti-human IgE (1:200). Analysis of immune sera on BCL1 or Sp2/0 transfected cell were always performed using samples yielding comparable ELISA values against the hu-CH3 portion. BCL1 lymphoma cells or Sp2/0 transfected cells were incubated at 4°C with different dilutions of immune sera in 3% BSA/PBS containing 0.02% NaN 3 . Bound antibodies were detected with FITC conjugated goat anti-mouse IgG (Kirkegaard and Perry). mAb 10/4A12 is a rat mAb specific for V H of BCL1. 21 Staining with mAb 10/4A12 was performed by incubation for 1 h (1:200) followed by a FITC-conjugated goat anti-rat IgG (Kirkegaard and Perry). Fluorescence analysis was performed with a FACScalibur (Becton Dickinson, San Jose, CA, USA).
Western blotting
Membrane extracts were obtained from 4 × 10 7 cells that were resuspended at a concentration of about 10 7 /ml in hypotonic buffer (20% PBS containing 0.25 m sucrose, 20 mm NEM and protease inhibitors) and lysed by three freeze/thawing cycles. The suspension was centrifuged 10 min at 700 g to separate nuclei and unlysed cells, and the supernatant was ultracentrifuged for 1 h at 100 000 g. The membrane pellet was resuspended in 400 l of TNN buffer (50 mm Tris HCl pH 8.0, 250 mm NaCl, 0.5% NP40) containing 20 mm NEM and protease inhibitors (1 mm phenyl-methyl-sulfonyl-fluoride, 0.8 m aprotinin, 40 m bestatin, 22 m leupeptin and 15 m pepstatin A, all from Sigma). 30 l of this membrane extract was separated in SDS polyacrylamide gel electrophoresis in reducing conditions, transferred to PVDF membrane, and probed with either protein-induced or DNA-induced anti-Id BCL1 serum, followed by peroxidase-conjugated rabbit antimouse IgG (Dako) and detected with the ECL chemiluminescent reagent (Amersham-Pharmacia Biotech). also thank Facundo Batista and Luca Vangelista for helpful comments on the manuscript.
